Stryker Corporation
SYK
$294.66
+0.49%
Stryker Corporation designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices, spanning reconstructive orthopaedics (hip and knee replacements, extremities), MedSurg (endoscopy systems, operating room equipment, hospital beds and gurneys), and neurovascular/robotics (embolic coils, mechanical thrombectomy systems, orthopedic robotics). It is one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment, with roughly one-fourth of revenue generated outside the United States and a workforce of approximately 56,000 employees. The current investor narrative is dominated by a sharp divergence between the company's solid operating execution and a badly deteriorating share price: Stryker completed the acquisition of Amplitude Vascular Systems in May 2026 to add next-generation intravascular lithotripsy technology to its peripheral vascular portfolio, and Q2 2026 revenue grew 9.4% year-over-year to $6.59 billion with gross margin expanding to 68.3%. Despite this, the stock has fallen roughly 25% over the past year and 20% year-to-date, underperforming the S&P 500 by over 41 percentage points on a relative-strength basis, leaving investors debating whether this is a compelling dislocation in a high-quality medtech compounder or an early signal of structural margin and growth pressure.…
SYK
Stryker Corporation
$294.66
Related headlines
Investment Opinion: Should I buy SYK Today?
The synthesized recommendation is a Hold, with a bias toward accumulation on weakness. The core thesis is that Stryker remains a high-quality medtech compounder with strong fundamentals, but the current valuation and recent price weakness suggest a balanced risk/reward. The analyst consensus rating of 'Buy' with an average target price of $366.15 implies 32% upside, but the stock's severe underperformance and elevated multiples warrant caution.
Supporting evidence includes Q2 2026 revenue growth of 9.4% year-over-year, gross margin expansion to 68.3%, and free cash flow of $4.70 billion. The forward P/E of 16.6 is reasonable if earnings grow as expected, but the PEG ratio of 5.16 indicates the stock is expensive relative to its growth rate. The dividend yield of 0.96% is modest but sustainable with a payout ratio of 39.6%. The implied upside to the analyst average target is substantial, but the low target of $298 offers only 7.5% upside, suggesting limited margin of safety.
Key risks include earnings volatility, with trailing twelve-month EPS of $0.024, and debt-to-equity of 0.73. The rating would upgrade to Buy if the stock price falls below $250, improving the risk/reward, or if revenue growth accelerates above 10% with margin expansion. It would downgrade to Sell if revenue growth decelerates below 5% or if gross margins fall below 65%. Relative to its history and peers, the stock appears overvalued on a trailing basis but fairly valued on a forward basis, assuming earnings materialize.
Sign up to view all
SYK 12-Month Price Forecast
Stryker presents a mixed picture: strong revenue growth and margin expansion contrast with earnings volatility and severe stock underperformance. The forward valuation is reasonable if earnings materialize, but the high PEG ratio and recent price weakness suggest caution. The analyst consensus is bullish, but the market's skepticism is evident in the relative strength metrics. I would upgrade to bullish if the company demonstrates consistent earnings growth and margin sustainability, and downgrade to bearish if revenue growth falls below 5% or margins contract significantly.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $362.62 and implied upside of +23.1% versus the current price.
Average Target
$362.62
0 analysts
Implied Upside
+23.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$298 - $465
Analyst target range
Drowning in data?
Find the real signal!
Bulls vs Bears: SYK Investment Factors
The bear case currently has stronger evidence due to the stock's severe underperformance, elevated valuation multiples, and earnings volatility. However, the bull case is supported by solid revenue growth, margin expansion, and a strong analyst consensus. The most critical tension is whether the recent margin expansion and revenue growth can be sustained to justify the premium valuation, or if the stock is due for a further de-rating. Resolving this tension will determine whether SYK is a value trap or a compelling turnaround.
Bullish
- Revenue Growth Accelerating: Q2 2026 revenue grew 9.4% year-over-year to $6.59 billion, up from $6.02 billion in Q2 2025. This acceleration from the prior year's growth rate suggests underlying demand remains robust despite macro pressures.
- Gross Margin Expansion: Gross margin expanded to 68.3% in Q2 2026 from 62.3% in Q2 2025, a 600 basis point improvement. This significant margin expansion demonstrates pricing power and operational efficiency gains.
- Strong Free Cash Flow: The company generated $4.70 billion in trailing twelve-month free cash flow, providing ample resources for dividends, buybacks, and strategic acquisitions like Amplitude Vascular Systems.
- Analyst Consensus Buy Rating: 26 analysts rate the stock a 'Buy' with an average target price of $366.15, implying 32% upside from the current price of $277.33. The low target of $298 still represents 7.5% upside.
Bearish
- Severe Relative Underperformance: SYK has underperformed the S&P 500 by 41.09 percentage points over the past year and 34.52 percentage points year-to-date. This persistent weakness suggests deep-seated investor concerns beyond temporary market fluctuations.
- Elevated Valuation Metrics: The trailing P/E ratio is 41.4, and the forward P/E is 16.6, but the PEG ratio of 5.16 indicates the stock is expensive relative to its growth rate. The price-to-sales ratio of 5.35 is also high for a company with single-digit revenue growth.
- Earnings Volatility and EPS Miss: The trailing twelve-month EPS is only $0.024, far below the quarterly EPS figures, suggesting significant one-time charges or accounting adjustments. Q1 2026 EPS of $1.95 was well below Q2's $3.32, highlighting earnings instability.
- Debt Burden and Interest Expenses: Debt-to-equity stands at 0.73, and interest expenses were $148 million in Q1 2026 alone. This leverage could strain profitability if interest rates remain elevated or if cash flows decline.
SYK Technical Analysis
Beta
0.78
0.78x market volatility
Max Drawdown
-30.6%
Largest decline past year
52-Week Range
$267-$393
Price range past year
Annual Return
-20.2%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +3.5% | +1.2% |
| 3m | -7.9% | +2.7% |
| 6m | -14.2% | +7.5% |
| 1y | -20.2% | +15.5% |
| ytd | -15.4% | +11.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Quarterly Revenue
$6.6B
2026-06
Revenue YoY Growth
+9.4%
YoY Comparison
Gross Margin
68.3%
Latest Quarter
Free Cash Flow
$4.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are significant, primarily due to the company's debt load and earnings volatility. With a debt-to-equity ratio of 0.73 and interest expenses of $148 million in Q1 2026, Stryker's leverage could pressure profitability if cash flows decline. Additionally, the trailing twelve-month EPS of $0.024 contrasts sharply with quarterly EPS figures, indicating potential one-time charges or accounting irregularities that could undermine investor confidence. The company's reliance on continued revenue growth to justify its valuation is another risk, as any deceleration could trigger a sharp sell-off.
Market and competitive risks are heightened by Stryker's premium valuation and sector rotation dynamics. The stock trades at a trailing P/E of 41.4 and a price-to-sales ratio of 5.35, well above historical averages for the medical device sector, leaving it vulnerable to multiple compression if growth slows. The beta of 0.781 suggests lower market correlation, but the stock has still underperformed the S&P 500 by over 41 percentage points in the past year, indicating company-specific issues. Competitive threats from peers like Boston Scientific, which recently faced trial setbacks, could shift market share, while regulatory headwinds in healthcare add uncertainty.
The worst-case scenario involves a combination of revenue deceleration, margin contraction, and multiple compression. If revenue growth falls below 5% and gross margins decline from 68.3%, the stock could retest its 52-week low of $267, representing a 3.7% decline from the current price. However, a more severe downturn could push the stock to the analyst low target of $298, which is actually above the current price, suggesting limited downside based on analyst estimates. A realistic bear case might see the stock fall to $250, a 9.8% drop, if earnings disappoint and the market re-rates the stock to a lower multiple.
FAQ
The key risks include financial risks such as high debt-to-equity of 0.73 and interest expenses of $148 million in Q1 2026, which could strain profitability. Operational risks include earnings volatility, as evidenced by the trailing twelve-month EPS of $0.024, and reliance on continued revenue growth to justify valuation. Competitive risks involve potential market share loss to peers like Boston Scientific, and regulatory risks in the healthcare sector. Macro risks include sensitivity to interest rates and economic downturns, though the low beta of 0.781 provides some defense. The most severe risk is a revenue deceleration below 5%, which could trigger a significant de-rating.
The 12-month forecast includes a bull case with 30% probability targeting $366-$465, a base case with 50% probability targeting $298-$366, and a bear case with 20% probability targeting $250-$298. The base case assumes revenue growth of 8% and stable margins, leading to a stock price around the analyst average target of $366. The bull case relies on successful integration of Amplitude Vascular Systems and margin expansion above 70%. The bear case involves revenue growth slowing below 5% and margin compression. The most likely scenario is the base case, with the key assumption being sustained execution and no major disruptions.
SYK appears overvalued on a trailing basis with a P/E of 41.4 and a price-to-sales ratio of 5.35, but fairly valued on a forward basis with a forward P/E of 16.6. The PEG ratio of 5.16 indicates the stock is expensive relative to its expected growth rate, suggesting the market is pricing in significant future earnings growth. Compared to peers in the medical device sector, SYK's valuation is at a premium, reflecting its leadership position and strong cash flow. However, the recent price decline has brought the valuation closer to historical averages, and if earnings meet estimates, the stock could be undervalued at current levels.
SYK may be a good buy for long-term investors who believe in the company's growth trajectory and are willing to tolerate short-term volatility. The stock trades at $277.33, with analysts projecting an average target of $366.15, implying 32% upside. However, the trailing P/E of 41.4 and PEG ratio of 5.16 suggest the stock is not cheap, and the 25% decline over the past year indicates underlying concerns. The biggest downside risk is a retest of the 52-week low of $267, a 3.7% drop, but a more severe scenario could see the stock fall to $250. For risk-averse investors, waiting for clearer signs of earnings stability and margin sustainability is prudent.
SYK is more suitable for long-term investment given its stable business model, consistent revenue growth, and defensive characteristics with a beta of 0.781. The company pays a modest dividend with a yield of 0.96% and a payout ratio of 39.6%, indicating a focus on reinvestment for growth. Short-term trading is less advisable due to earnings volatility and the stock's recent underperformance, which could persist. A minimum holding period of 2-3 years is recommended to allow for the realization of growth initiatives and potential multiple expansion. Investors should monitor quarterly earnings and margin trends to reassess the thesis.
